2015 Annual Meeting of the European Association for the Study of the Liver*

April 22-26, 2015; Vienna, Austria
CCO’s Independent Conference Coverage of EASL 2015 includes Capsule Summaries, expert faculty analysis of key studies, and downloadable slides.

HCV Approved Therapies


In this population of patients with advanced liver disease, ledipasvir/sofosbuvir plus ribavirin treatment was generally safe and well tolerated with low rates of treatment-related serious adverse events and treatment discontinuation due to adverse events.

Released: April 26, 2015

In patients receiving a broad range of sofosbuvir-containing regimens, SVR rates higher in patients without detectable Week 4 HCV RNA vs with detectable Week 4 HCV RNA; further analysis required.

Released: April 29, 2015

Early efficacy data from this small patient group, which included patients on hemodialysis, suggests treatment effective in subtype 1a and 1b populations.

Released: April 30, 2015

In patients with genotype 3 HCV infection, sofosbuvir plus pegIFN/RBV more effective than sofosbuvir plus RBV regimens regardless of treatment history or cirrhosis.

Released: April 28, 2015

SVR12 rates were 88% in treatment-naive patients and 79% in treatment-experienced patients—higher than historical controls with earlier approved DAA plus peginterferon/ribavirin-based regimens.

Released: April 30, 2015

Rates of anemia-related AEs, worsening renal function, and renal and urinary AEs increased across patient groups with decreasing renal function.

Released: April 26, 2015

While the 12-week regimen was effective regardless of HCV genotype 1 subtype or presence of Q80K mutation, efficacy was diminished when treatment was shortened to 8 weeks.

Released: April 30, 2015

In this observational cohort study, higher SVR12 rates with 12 weeks of sofosbuvir plus daclatasvir than sofosbuvir/ledipasvir among patients with genotype 3 HCV infection.

Released: April 24, 2015

In this open-label trial, SVR12 rates were numerically lower in patients with vs without baseline NS5A RAVs and in patients who received 12 vs 8 weeks of previous ledipasvir/sofosbuvir-based therapy.

Released: April 25, 2015

Among patients with genotype 1 HCV infection, sofosbuvir plus simeprevir was selected most commonly and associated with 74% SVR12.

Released: April 27, 2015

Ledipasvir/sofosbuvir effective with very low rates of serious adverse events and no treatment-related discontinuations in patients with genotype 4 or 5 HCV infection.

Released: April 27, 2015

Incidence of HCV reinfection 4.7/100 person-years among patients who relapsed to injection drug use vs 1.8/100 person-years among those with any previous injection drug use.

Released: April 26, 2015

In multivariate analysis, black race only factor associated with treatment failure.

Released: April 26, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Gilead Sciences
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?